Mthfr C677t Polymorphism Associated with Breast Cancer Susceptibility: A Meta-Analysis Involving 15,260 Cases and 20,411 Controls
Jian Zhang,Li-Xin Qiu,Zhong-Hua Wang,Xiang-Hua Wu,Xiao-Jian Liu,Bi-Yun Wang,Xi-Chun Hu
DOI: https://doi.org/10.1007/s10549-010-0783-5
2010-01-01
Breast Cancer Research and Treatment
Abstract:Published data on the association between MTHFR C677T polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched. Crude ORs with 95% CIs were used to assess the strength of association between the MTHFR C677T polymorphism and breast cancer risk. The pooled ORs were performed with co-dominant model (CT vs. CC, TT vs. CC), dominant model (CT + TT vs. CC), and recessive model (TT vs. CC + CT), respectively. A total of 37 studies including 15,260 cases and 20,411 controls were involved in this meta-analysis. Overall, significantly elevated breast cancer risk was associated with TT variant genotype in homozygote comparison and dominant genetic model when all studies were pooled into the meta-analysis (TT vs. CC: OR = 1.11, 95% CI = 1.01-1.23; dominant model: OR = 1.04, 95% CI = 1.00-1.09). In the subgroup analysis by ethnicity, significantly increased risks were found for TT allele carriers among Asians (TT vs. CC: OR = 1.18, 95% CI = 1.04-1.35; recessive model: OR = 1.15, 95% CI = 1.03-1.29). When stratified by study design, statistically significantly elevated risk was found in hospital-based studies (TT vs. CC: OR = 1.18, 95% CI = 1.02-1.38; recessive model: OR = 1.17, 95% CI = 1.05-1.29). In the subgroup analysis by menopausal status, statistically significantly increased risk was found among postmenopausal women (CT vs. CC: OR = 1.12, 95% CI = 1.02-1.23; dominant model: OR = 1.11, 95% CI = 1.01-1.22). In conclusion, this meta-analysis suggests that the MTHFR T allele is a low-penetrant risk factor for developing breast cancer.